Recombinant human L-Ficolin directly neutralizes hepatitis C virus entry

Journal of Innate Immunity

Volumn 6, Issue 5, 2014, Pages 676-684

  Hamed, Mohamed R ^a,d   Brown, Richard J P ^a   Zothner, Carsten ^b   Urbanowicz, Richard A ^a   Mason, Christopher P ^a   Krarup, Anders ^c   McClure, C Patrick ^a   Irving, William L ^a   Ball, Jonathan K ^a   Harris, Mark ^b   Hickling, Timothy P ^a   Tarr, Alexander W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Ficolin; Glycosylation; Hepatitis C virus; Neutralization; Virus entry

Indexed keywords

ANTIVIRUS AGENT; CALCIUM; FICOLIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; L FICOLIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; E1 PROTEIN, HEPATITIS C VIRUS; GLYCOPROTEIN E2, HEPATITIS C VIRUS; LECTIN; PATTERN RECOGNITION RECEPTOR; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN; OLIGOMER; RECOMBINANT L FICOLIN;

ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL CULTURE; CIRCULATION; COMPLEMENT LECTIN PATHWAY; GROWTH INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS NEUTRALIZATION; DRUG EFFECTS; HEK293 CELL LINE; HEPACIVIRUS; IMMUNOLOGY; LIVER; METABOLISM; PATHOGENICITY; PHYSIOLOGY; TRANSMISSION; VIROLOGY; VIRULENCE; PROTEIN BINDING; PROTEIN PURIFICATION;

COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; HEK293 CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; LECTINS; LIVER; PROTEIN BINDING; RECEPTORS, PATTERN RECOGNITION; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS; VIRULENCE; VIRUS INTERNALIZATION;

EID: 84906937351     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000362209     Document Type: Article

References (41)

1. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM: Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
2. Londono MC, Crespo G, Forns X: Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Curr Opin Organ Transplant 2013; 18: 271-278.
3. Edwards VC, Tarr AW, Urbanowicz RA, Ball JK: The role of neutralizing antibodies in hepatitis C virus infection. J Gen Virol 2012; 93: 1-19.
4. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
5. Bartosch B, Dubuisson J, Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
6. Penin F, Dubuisson J , Rey FA, Moradpour D, Pawlotsky JM: Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.
7. Iacob RE, Perdivara I, Przybylski M, Tomer KB: Mass spectrometric chara cterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J Am Soc Mass Spectrom 2008; 19: 428-444.
8. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J: Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 2005; 79: 8400-8409.
9. Helle F, Vieyres G , Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J: Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions . J Virol 2010; 84: 11905-11915.
10. Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH, Arnold JN, Ball JK, Sim RB, Tarr AW, Hickling TP: Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 2010; 1: 664-674.
11. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J: Cyanovirin -N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006; 281: 25177-25183.
12. Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J: Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother 2011; 55: 5159-5167.
13. Holmskov U, Thiel S, Jensenius JC: Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21: 547-578.
14. Krarup A, Mitchell DA, Sim RB: Recognition of acetylated oligosaccharides by human Lficolin. Immunol Lett 2008; 118: 152-156.
15. Matsushita M, Fujita T: Ficolins and the lectin complement pathway. Immunol Rev 2001; 180: 78-85.
16. Garlatti V, Belloy N, Martin L, Lacroix M, Matsushita M, Endo Y, Fujita T, Fontecilla-Camps JC, Arlaud GJ, Thielens NM, Gaboriaud C: Structur al insights into the innate immune recognition specificities of L-and Hficolins. EMBO J 2007; 26: 623-633.
17. Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Miz uochi T: A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin. J Biol Chem 1996; 271: 2448-2454.
18. Le Y, Lee SH, Kon OL, Lu J: Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogenlike (FBG) domain. FEBS Lett 1998; 425: 367-370.
19. Roozendaal R, Carroll MC: Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 2007; 219: 157-166.
20. Keirstead ND, Lee C, Yoo D, Brooks AS, Hayes MA: Porcine pl asma ficolin binds and reduces infectivity of porcine reproductive and respiratory syndrome virus (PRRSV) in vitro. Antiviral Res 2008; 77: 28-38.
21. Pan Q, Chen H, Wang F, Jeza VT, Hou W, Zha o Y, Xiang T, Zhu Y, Endo Y, Fujita T, Zhang XL: L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun 2012; 4: 312-324.
22. Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang X: Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol 2009; 6: 235-244.
23. Cseh S, Vera L, Matsushita M, Fujita T, Arlaud GJ, Thielens NM: Characterization of the interaction between L-fico lin/p35 and mannan-binding lectin-associated serine proteases-1 and-2. J Immunol 2002; 169: 5735-5743.
24. Michalak JP, Wychowski C, Choukhi A, Meunier JC, Ung S, Rice CM, Dubuisson J: Characterization of truncated forms of hepatitis C virus glycoproteins. J Gen Virol 1997; 78: 2299-2306.
25. Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, Vitelli A, Dubuisson J, Patel AH, Ball JK, Borrow P: Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J Gen Virol 2005; 86: 2507-2512.
26. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH: Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 20 05; 79: 11095-11104.
27. Tarr AW, Urbanowicz RA, Hamed MR, Albecka A, McClure CP, Brown RJ, Irving WL, Dubuisson J, Ball JK: Hepatitis C patient-derived glycoproteins exhibit marked diff erences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. J Virol 2011; 85: 4246-4257.
28. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72: 2855-2864.
29. Lindenbach BD, Evan s MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
30. Hummelshoj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P: Molecular organization of human Ficolin-2. Mol Immunol 2007; 44: 401-411.
31. Yanagi M, Purc ell RH, Emerson SU, Bukh J: Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 1997; 94: 8738-8743.
32. Krarup A, Thiel S, Hansen A, Fujita T, Jensenius JC: L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem 2004; 279: 47513-47519.
33. Matsushi ta M, Endo Y, Fujita T: Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol 2000; 164: 2281-2284.
34. Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, Wychowski C, Dubuisson J: Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem 199 8; 273: 32088-32095.
35. Goffard A,Dubuisson J: Glycosylation of hepatitis C virus envelope proteins. Biochimie. 2003; 85: 295-301.
36. Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T: An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013; 58: 932-939.
37. Garlatti V, Martin L, Gout E, Reiser JB, Fujita T, Arlaud GJ, Thielens NM, Gaboriaud C: Structural basis for innate immune sensing by M-ficolin and its control by a pH-depe ndent conformational switch. J Biol Chem 2007; 282: 35814-35820.
38. Marzi A, Mitchell DA, Chaipan C, Fisch T, Doms RW, Carrington M, Desrosiers RC, Pohlmann S: Modulation of HIV a nd SIV neutralization sensitivity by DC-SIGN and mannosebinding lectin. Virology 2007; 368: 322-330.
39. Mehlhop E, Diamond MS: Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 2006; 203: 1371-1381.
40. Amet T, Ghabril M, Chalasani N, Byrd D, Hu N, Grantham A, Liu Z, Qin X, He JJ, Yu Q: CD59 incorporation p rotects hepatitis C virus against complement-mediated destruction. Hepatology 2012; 55: 354-363.
41. Kilpatrick DC, Fujita T, Matsushita M: P35, an opsonic lectin of the ficolin family, in human bloo d from neonates, normal adults, and recurrent miscarriage patients. Immunol Lett 1999; 67: 109-112.